BXCL501 not checked

BioXcel Therapeutics Inc

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1 trial completes
Trials
18 active
31 in total · 22 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Sublingual film containing 60 Micrograms BXCL501 Europe Only”In the company’s words, NCT05025605 on ClinicalTrials.gov
Tested for
Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Main trialPhase 1
“This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.”In the company’s words, NCT05025605 on ClinicalTrials.gov
Other names
Dexmedetomidine

Other drugs for Schizophrenia

All 39 drugs for Schizophrenia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials31

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Jul 2027 Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Phase 3Completed 21 Apr 2023 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
Phase 3Terminated 11 Sep 2023 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
Phase 3Completed 15 Aug 2025 Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
Phase 2Withdrawn 21 Feb 2022 Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
Phase 2Terminated 1 Apr 2022 An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Phase 2Completed 7 Oct 2025 Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
Phase 1/2Completed 24 Jan 2022 Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Phase 1Completed 31 Jul 2019 Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
Phase 4Authorised not given Effects of an Opioid Sparing Care Pathway for Patients undergoing Obesity Surgery
Phase 3/4Not authorised not given Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial.
Phase 3/4Ended not given Comparison of different doses of perineural dexmedetomidine as adjuvans to ropivacaine 0,67% for interscalene plexus block in association with 10 mg intravenous dexamethasone: a single center, double blinded, randomised controlled trial.
Phase 2Authorised not given Influence of Dexmedetomidine on the Human Glymphatic Cerebrospinal Fluid Flow, Neural Activity and Cerebral Blood Flow in Functional Magnetic Resonance Imaging (GlymphDex)
Phase 2Authorised not given Pain Relief at Screening for Retinopathy of Prematurity - The PROPER study
Phase 3Authorised not given Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation
Phase 2/3Authorised not given Advancing the quality of treatment and care for acute agitation in emergency psychiatry
Phase 3/4Authorised not given Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial
Phase 4Authorised not given The effect of nocturnal dexmedetomidine on postoperative sleep quality and fatigue after major surgery in elderly patients: DEXSLEEP study
Phase 3Ended not given Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID)
Phase 3Ended not given Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children
Phase 2Authorised not given Intravenous dexmedetomidine as an adjuvant to locoregional anesthesia in pediatric surgery: a prospective, randomized, double-blind, placebo-controlled study. DEXPED
Phase 4Authorised not given Intranasal dexmedetomidine sedation and analgesia during minor procedures in the pediatric emergency room: Randomized double-blinded clinical trial
Phase 3Authorised not given Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial
Phase 4Halted not given Opioid-Free General Anesthesia Compared to Opioid-Based General Anesthesia for the Reduction of Postoperative Nausea and Vomiting in Patients Undergoing Robotic Bariatric Surgery - ANGELO Study
Phase 2Authorised not given The use of intranasal dexmedetomidine for pediatric sedation in non-invasive radiological procedures (CTMS 004321) Assessing the efficacy and safety profile of intranasal dexmedetomidine for procedural sedation in radiological procedures in children with a prospective exploratory interventional monocentric study in a tertiary center in Antwerp (Belgium)
Phase 4Authorised not given Incidence and severity of postoperative delirium associated with Dexmedetomidine sedation during femur osteosynthesis in the elderly population
Phase 4Authorised not given Is magnesium sulfate an alternative with an analgesic and safety profile equivalent to dexmedetomidine as an adjuvant to ropivacaine in erector block in mastectomy?
Phase 3Authorised not given Efficacy of Dexmedetomidine on Emergence Delirium in Children Undergoing Adenotonsillectomy: A Double-Blind Randomized Controlled Trial with Heart Rate Variability and Electroencephalography-Guided Anesthesia
Phase 3Authorised not given ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial
Phase 3/4Authorised not given OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery
Phase 2Authorised not given DEXmedetomidine to Improve Neurologic Injury of patients after out-of-hospital cardiac arrest – a phase II randomized, double blind, placebo-controlled, parallel group trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BXCL501

Following is part of Solo: you see every change to BXCL501 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in